These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 29310346)

  • 1. A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.
    Korol S; Mottet F; Perreault S; Baker WL; White M; de Denus S
    Medicine (Baltimore); 2017 Dec; 96(48):e8719. PubMed ID: 29310346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative Efficacy of Spironolactone, Eplerenone, and cAnRenone in patients with Chronic Heart failure (RESEARCH): a systematic review and network meta-analysis of randomized controlled trials.
    Frankenstein L; Seide S; Täger T; Jensen K; Fröhlich H; Clark AL; Seiz M; Katus HA; Nee P; Uhlmann L; Naci H; Atar D
    Heart Fail Rev; 2020 Mar; 25(2):161-171. PubMed ID: 31364027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A systematic review and economic evaluation of the clinical effectiveness and cost-effectiveness of aldosterone antagonists for postmyocardial infarction heart failure.
    McKenna C; Burch J; Suekarran S; Walker S; Bakhai A; Witte K; Harden M; Wright K; Woolacott N; Lorgelly P; Fenwick L; Palmer S
    Health Technol Assess; 2010 May; 14(24):1-162. PubMed ID: 20492762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: a systematic review and network meta-analysis of 32 randomized trials.
    Pamporis K; Karakasis P; Sagris M; Zarifis I; Bougioukas KI; Pagkalidou E; Milaras N; Samaras A; Theofilis P; Fragakis N; Tousoulis D; Xanthos T; Giannakoulas G
    Curr Probl Cardiol; 2024 Jul; 49(7):102615. PubMed ID: 38692445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effects of selective and non-selective mineralocorticoid antagonism on glucose homeostasis of heart failure patients with glucose intolerance or type II diabetes: A randomized controlled double-blind trial.
    Korol S; White M; O'Meara E; Tournoux F; Racine N; Ducharme A; Rouleau JL; Liszkowski M; Mansour A; Jutras M; Guertin MC; Bernier M; Lavoie J; Leclair G; Neagoe PE; Chaar D; Sirois MG; de Denus S
    Am Heart J; 2018 Oct; 204():190-195. PubMed ID: 30097164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
    Chung EY; Ruospo M; Natale P; Bolignano D; Navaneethan SD; Palmer SC; Strippoli GF
    Cochrane Database Syst Rev; 2020 Oct; 10(10):CD007004. PubMed ID: 33107592
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid Antagonists in ESRD: An Overview of Clinical Trial Evidence.
    Georgianos PI; Vaios V; Eleftheriadis T; Zebekakis P; Liakopoulos V
    Curr Vasc Pharmacol; 2017; 15(6):599-606. PubMed ID: 28155610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.
    Quach K; Lvtvyn L; Baigent C; Bueti J; Garg AX; Hawley C; Haynes R; Manns B; Perkovic V; Rabbat CG; Wald R; Walsh M
    Am J Kidney Dis; 2016 Oct; 68(4):591-598. PubMed ID: 27265777
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mineralocorticoid receptor antagonists in heart failure with preserved ejection fraction (HFpEF).
    Capuano A; Scavone C; Vitale C; Sportiello L; Rossi F; Rosano GM; Coats AJ
    Int J Cardiol; 2015 Dec; 200():15-9. PubMed ID: 26404747
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Spironolactone and glucose metabolism, a systematic review and meta-analysis of randomized controlled trials.
    Zhao JV; Xu L; Lin SL; Schooling CM
    J Am Soc Hypertens; 2016 Aug; 10(8):671-82. PubMed ID: 27372428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Selection of a mineralocorticoid receptor antagonist for patients with hypertension or heart failure.
    Iqbal J; Parviz Y; Pitt B; Newell-Price J; Al-Mohammad A; Zannad F
    Eur J Heart Fail; 2014 Feb; 16(2):143-50. PubMed ID: 24464876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Eplerenone is not superior to older and less expensive aldosterone antagonists.
    Chatterjee S; Moeller C; Shah N; Bolorunduro O; Lichstein E; Moskovits N; Mukherjee D
    Am J Med; 2012 Aug; 125(8):817-25. PubMed ID: 22840667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Converging indications of aldosterone antagonists (spironolactone and eplerenone): a narrative review of safety profiles.
    Danjuma MI; Mukherjee I; Makaronidis J; Osula S
    Curr Hypertens Rep; 2014 Feb; 16(2):414. PubMed ID: 24407447
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy and safety of mineralocorticoid receptor antagonists in heart failure: a network meta-analysis of randomized controlled trials.
    Yang P; Shen W; Chen X; Zhu D; Xu X; Wu T; Xu G; Wu Q
    Heart Fail Rev; 2019 Sep; 24(5):637-646. PubMed ID: 31030322
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroidal and Novel Non-steroidal Mineralocorticoid Receptor Antagonists in Heart Failure and Cardiorenal Diseases: Comparison at Bench and Bedside.
    Kolkhof P; Jaisser F; Kim SY; Filippatos G; Nowack C; Pitt B
    Handb Exp Pharmacol; 2017; 243():271-305. PubMed ID: 27830348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension.
    Pelliccia F; Rosano G; Patti G; Volterrani M; Greco C; Gaudio C
    Int J Cardiol; 2015 Dec; 200():8-11. PubMed ID: 25466561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of eplerenone versus spironolactone on cortisol and hemoglobin A₁(c) levels in patients with chronic heart failure.
    Yamaji M; Tsutamoto T; Kawahara C; Nishiyama K; Yamamoto T; Fujii M; Horie M
    Am Heart J; 2010 Nov; 160(5):915-21. PubMed ID: 21095280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Eplerenone: a selective aldosterone receptor antagonist for patients with heart failure.
    Barnes BJ; Howard PA
    Ann Pharmacother; 2005 Jan; 39(1):68-76. PubMed ID: 15590870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mineralocorticoid receptor antagonists and atrial fibrillation: a meta-analysis.
    Liu T; Korantzopoulos P; Shao Q; Zhang Z; Letsas KP; Li G
    Europace; 2016 May; 18(5):672-8. PubMed ID: 26705563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eplerenone: a selective aldosterone receptor antagonist for hypertension and heart failure.
    Moore TD; Nawarskas JJ; Anderson JR
    Heart Dis; 2003; 5(5):354-63. PubMed ID: 14503934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.